Print

Search Results: Treatment + Breast Cancer + Stage 2 or 3 (4 results)

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/285/

Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.  

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

https://www.facingourrisk.org/research-clinical-trials/study/56/radcomp-a-study-at-the-heart-of-breast-cancer-treatment

Treatment

The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

Additional Results on Clinicaltrials.gov Treatment + Breast Cancer + Stage 2 or 3
66 results

Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
NCT ID: NCT04443413 (https://classic.clinicaltrials.gov/show/NCT04443413)

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://classic.clinicaltrials.gov/show/NCT05288777)

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT ID: NCT05710328 (https://classic.clinicaltrials.gov/show/NCT05710328)

Ultrahypofractionation and Normal Tissue Toxicity
NCT ID: NCT05912231 (https://classic.clinicaltrials.gov/show/NCT05912231)

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://classic.clinicaltrials.gov/show/NCT06006806)

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT ID: NCT03979508 (https://classic.clinicaltrials.gov/show/NCT03979508)

SABR-CaRe in Early Stage Breast Cancer
NCT ID: NCT04959474 (https://classic.clinicaltrials.gov/show/NCT04959474)

Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://classic.clinicaltrials.gov/show/NCT06275126)

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
NCT ID: NCT02927912 (https://classic.clinicaltrials.gov/show/NCT02927912)

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery
NCT ID: NCT01570998 (https://classic.clinicaltrials.gov/show/NCT01570998)

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT ID: NCT05098210 (https://classic.clinicaltrials.gov/show/NCT05098210)

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
NCT ID: NCT04674306 (https://classic.clinicaltrials.gov/show/NCT04674306)

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://classic.clinicaltrials.gov/show/NCT04329065)

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT ID: NCT04993313 (https://classic.clinicaltrials.gov/show/NCT04993313)

Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://classic.clinicaltrials.gov/show/NCT03804944)

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT ID: NCT04197687 (https://classic.clinicaltrials.gov/show/NCT04197687)

Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
NCT ID: NCT04871516 (https://classic.clinicaltrials.gov/show/NCT04871516)

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT ID: NCT04266249 (https://classic.clinicaltrials.gov/show/NCT04266249)

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
NCT ID: NCT05190770 (https://classic.clinicaltrials.gov/show/NCT05190770)

TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://classic.clinicaltrials.gov/show/NCT05795101)

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT ID: NCT02760030 (https://classic.clinicaltrials.gov/show/NCT02760030)

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT ID: NCT05595499 (https://classic.clinicaltrials.gov/show/NCT05595499)

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT ID: NCT02912312 (https://classic.clinicaltrials.gov/show/NCT02912312)

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
NCT ID: NCT05455658 (https://classic.clinicaltrials.gov/show/NCT05455658)

Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT ID: NCT04648904 (https://classic.clinicaltrials.gov/show/NCT04648904)

Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer
NCT ID: NCT04364672 (https://classic.clinicaltrials.gov/show/NCT04364672)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT ID: NCT06058377 (https://classic.clinicaltrials.gov/show/NCT06058377)

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://classic.clinicaltrials.gov/show/NCT04553770)

Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT ID: NCT02945579 (https://classic.clinicaltrials.gov/show/NCT02945579)

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://classic.clinicaltrials.gov/show/NCT05677802)

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://classic.clinicaltrials.gov/show/NCT05319873)

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
NCT ID: NCT03941756 (https://classic.clinicaltrials.gov/show/NCT03941756)

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://classic.clinicaltrials.gov/show/NCT05929768)

Metformin and Nightly Fasting in Women With Early Breast Cancer
NCT ID: NCT05023967 (https://classic.clinicaltrials.gov/show/NCT05023967)

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://classic.clinicaltrials.gov/show/NCT05673200)

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT ID: NCT06245889 (https://classic.clinicaltrials.gov/show/NCT06245889)

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT ID: NCT05568472 (https://classic.clinicaltrials.gov/show/NCT05568472)

Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
NCT ID: NCT04549571 (https://classic.clinicaltrials.gov/show/NCT04549571)

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID: NCT05812807 (https://classic.clinicaltrials.gov/show/NCT05812807)

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT ID: NCT06042569 (https://classic.clinicaltrials.gov/show/NCT06042569)

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT ID: NCT05069038 (https://classic.clinicaltrials.gov/show/NCT05069038)

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
NCT ID: NCT04119024 (https://classic.clinicaltrials.gov/show/NCT04119024)

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT ID: NCT03428802 (https://classic.clinicaltrials.gov/show/NCT03428802)

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://classic.clinicaltrials.gov/show/NCT04673448)

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT ID: NCT04457596 (https://classic.clinicaltrials.gov/show/NCT04457596)

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://classic.clinicaltrials.gov/show/NCT05269381)

DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT04567420 (https://classic.clinicaltrials.gov/show/NCT04567420)

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT ID: NCT04205903 (https://classic.clinicaltrials.gov/show/NCT04205903)

MARGetuximab Or Trastuzumab (MARGOT)
NCT ID: NCT04425018 (https://classic.clinicaltrials.gov/show/NCT04425018)

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT ID: NCT04862585 (https://classic.clinicaltrials.gov/show/NCT04862585)

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://classic.clinicaltrials.gov/show/NCT04090567)

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT ID: NCT02276443 (https://classic.clinicaltrials.gov/show/NCT02276443)

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT ID: NCT05020860 (https://classic.clinicaltrials.gov/show/NCT05020860)

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://classic.clinicaltrials.gov/show/NCT04704661)

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://classic.clinicaltrials.gov/show/NCT05092373)

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT ID: NCT04584255 (https://classic.clinicaltrials.gov/show/NCT04584255)

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT ID: NCT03971409 (https://classic.clinicaltrials.gov/show/NCT03971409)

Researching the Effect of Exercise on Cancer
NCT ID: NCT04589468 (https://classic.clinicaltrials.gov/show/NCT04589468)

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://classic.clinicaltrials.gov/show/NCT04550494)

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://classic.clinicaltrials.gov/show/NCT05464810)

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://classic.clinicaltrials.gov/show/NCT03424005)

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://classic.clinicaltrials.gov/show/NCT04802759)

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://classic.clinicaltrials.gov/show/NCT05607004)

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT ID: NCT02488967 (https://classic.clinicaltrials.gov/show/NCT02488967)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://classic.clinicaltrials.gov/show/NCT05564377)

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://classic.clinicaltrials.gov/show/NCT04771520)

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.